Overcoming the funding challenge: The cost of randomized controlled trials in the next decade

Journal of Bone and Joint Surgery

Volumn 94, Issue SUPPL. 1, 2012, Pages 101-106

  Shore, Benjamin J ^a   Nasreddine, Adam Y ^a   Kocher, Mininder S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; FUNDING; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PLANNING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; REVIEW; ARTICLE; COST; COST CONTROL; ECONOMICS; FINANCIAL MANAGEMENT; HUMAN; ORGANIZATION AND MANAGEMENT; UNITED STATES;

COST CONTROL; COSTS AND COST ANALYSIS; HUMANS; ORTHOPEDIC PROCEDURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84866908603     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.00193     Document Type: Review

References (34)

1. Keehan S, Sisko A, Truffer C, Smith S, Cowan C, Poisal J, Clemens MK; National Health Expenditure Accounts Projections Team. Health spending projections through 2017: the baby-boom generation is coming to Medicare. Health Aff (Millwood). 2008;27:w145-55. (Pubitemid 351490375)
2. Eisenstein EL, Collins R, Cracknell BS, Podesta O, Reid ED, Sandercock P, Shakhov Y, Terrin ML, Sellers MA, Califf RM, Granger CB, Diaz R. Sensible approaches for reducing clinical trial costs. Clin Trials. 2008;5:75-84. (Pubitemid 351412376)
3. Holler B, Forgione DA, Baisden CE, Abramson DA, Calhoon JH. Interactive financial decision support for clinical research trials. J Health Care Finance. 2011; 37:25-37.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85. (Pubitemid 36279392)
5. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-2.
6. Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med. 2003;254:105-13. (Pubitemid 36900433)
7. Kocher MS, Zurakowski D. Clinical epidemiology and biostatistics: a primer for orthopaedic surgeons. J Bone Joint Surg Am. 2004;86:607-20. (Pubitemid 38269037)
8. Bhandari M, Richards RR, Sprague S, Schemitsch EH. The quality of reporting of randomized trials in the Journal of Bone and Joint Surgery from 1988 through 2000. J Bone Joint Surg Am. 2002;84:388-96.
9. Obremskey WT, Pappas N, Attallah-Wasif E, Tornetta P 3rd, Bhandari M. Level of evidence in orthopaedic journals. J Bone Joint Surg Am. 2005;87: 2632-8. (Pubitemid 41747029)
10. Francis T Jr, Korns RF, Voight RB, Boisen M, Hemphill FM, Napier JA, Tolchinsky E. An evaluation of the 1954 poliomyelitis vaccine trials. Am J Public Health Nations Health. 1955;45(5 Pt 2):1-63.
11. Chalmers TC, Matta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med. 1977;297:1091-6. (Pubitemid 8210468)
12. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius S, Li T, Ounpuu S, Perez AC, Sleight P, Svard R, Temple R, Tsouderous Y, Yunis C, Yusuf S. Specific barriers to the conduct of randomized trials. Clin Trials. 2008; 5:40-8. (Pubitemid 351412371)
13. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:1539-44. (Pubitemid 30318291)
14. Soucacos PN, Johnson EO, Babis G. Randomised controlled trials in orthopaedic surgery and traumatology: overview of parameters and pitfalls. Injury. 2008; 39:636-42.
15. Simunovic N, Devereaux PJ, Bhandari M. Design considerations for randomised trials in orthopaedic fracture surgery. Injury. 2008;39:696-704.
16. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276:637-9. (Pubitemid 26278070)
17. Moher D, Jones A, Lepage L. CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285: 1992-5.
18. Boutron I, Moher D, Tugwell P, Giraudeau B, Poiraudeau S, Nizard R, Ravaud P. A checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) was developed using consensus. J Clin Epidemiol. 2005;58:1233-40. (Pubitemid 41608539)
19. Chan S, Bhandari M. The quality of reporting of orthopaedic randomized trials with use of a checklist for nonpharmacological therapies. J Bone Joint Surg Am. 2007;89:1970-8. (Pubitemid 350195028)
20. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, Colthart IR, Ross S, Shepherd SM, Russell D. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess. 1999;3:1-143.
21. Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 2010;11:78.
22. Rendell JM, Merritt RD, Geddes JR. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane Database Syst Rev. 2007; 2:MR000021.
23. Detsky AS. Are clinical trials a cost-effective investment? JAMA. 1989;262: 1795-800. (Pubitemid 19239466)
24. Abraham NS, Young JM, Solomon MJ. A systematic review of reasons for nonentry of eligible patients into surgical randomized controlled trials. Surgery. 2006; 139:469-83.
25. Hatfield E, Dicks E, Parfrey P. Budgeting, funding, and managing clinical research projects. Methods Mol Biol. 2009;473:299-311.
26. Yusuf S, Bosch J. Independent design and conduct of clinical trials. Clin Trials. 2006;3:503-7.
27. Arca MJ, Teitelbaum DH, St Peter SD, Cowles R, Aspelund G, Cassidy LD, Barnhart D, Abdullah F. Research interests and funding of members of the American Pediatric Surgical Association: report from 2010 American Pediatric Surgical Association Outcomes and Clinical Trials Committee. J Pediatr Surg. 2010;45:1983-8.
28. Zerhouni EA. Research funding. NIH in the post-doubling era: realities and strategies. Science. 2006;314:1088-90. (Pubitemid 44789023)
29. Kocher MS, Kasser JR, Waters PM, Bae D, Snyder BD, Hresko MT, Hedequist D, Karlin L, Kim YJ, Murray MM, Millis MB, Emans JB, Dichtel L, Matheney T, Lee BM. Lateral entry compared with medial and lateral entry pin fixation for completely displaced supracondylar humeral fractures in children. A randomized clinical trial. J Bone Joint Surg Am. 2007;89:706-12. (Pubitemid 46564272)
30. Califf RM. Clinical trials bureaucracy: unintended consequences of wellintentioned policy. Clin Trials. 2006;3:496-502.
31. Antman K, Lagakos S, Drazen J. Designing and funding clinical trials of novel therapies. N Engl J Med. 2001;344:762-3. (Pubitemid 32204996)
32. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;7:9.
33. McDonald AM, Treweek S, Shakur H, Free C, Knight R, Speed C, Campbell MK. Using a business model approach and marketing techniques for recruitment to clinical trials. Trials. 2011;12:74.
34. Francis D, Roberts I, Elbourne DR, Shakur H, Knight RC, Garcia J, Snowdon C, Entwistle VA, McDonald AM, Grant AM, Campbell MK. Marketing and clinical trials: a case study. Trials. 2007;8:37.